10x Genomics (TXG) Consolidated Net Income (2018 - 2026)

10x Genomics (TXG) has 9 years of Consolidated Net Income data on file, last reported at -$13.5 million in Q1 2026.

• For the quarter ending Q1 2026, Consolidated Net Income rose 60.8% year-over-year to -$13.5 million; the trailing twelve-month figure through Mar 2026 stood at -$22.7 million (up 85.57% YoY), and the FY2025 full-year result was -$43.5 million, up 76.16% from the prior year.
• Consolidated Net Income climbed to -$13.5 million in Q1 2026, from -$16.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $34.5 million in Q2 2025 to a low of -$93.0 million in Q3 2023.
• A 5-year average of -$38.9 million and a median of -$41.9 million in 2022 frame the typical range for Consolidated Net Income.
• Across the five-year window, Consolidated Net Income tumbled 483.22% in 2022 and surged 191.14% in 2025, its largest moves.
• Tracing TXG's Consolidated Net Income over 5 years: stood at -$17.2 million in 2022, then plunged by 184.36% to -$49.0 million in 2023, then slipped by 0.16% to -$49.0 million in 2024, then jumped by 66.85% to -$16.3 million in 2025, then increased by 17.12% to -$13.5 million in 2026.
• Business Quant data shows TXG's Consolidated Net Income at -$13.5 million in Q1 2026, -$16.3 million in Q4 2025, and -$27.5 million in Q3 2025.